Voyager Therapeutics (VYGR) Research & Development (2014 - 2026)

Voyager Therapeutics has disclosed Research & Development across 13 years of filings, most recently posting $24.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $24.6 million, down 21.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.8 million (down 3.07% YoY), and the FY2025 annual result was $134.7 million, up 5.74% from the prior year.
• Research & Development came in at $24.6 million for Q1 2026 at Voyager Therapeutics, down from $36.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $36.0 million in Q4 2025 to a low of $12.5 million in Q2 2022.
• The 5-year median for Research & Development is $25.9 million (2023), against an average of $25.9 million.
• Across the five-year window, Research & Development tumbled 35.79% in 2022 and surged 77.01% in 2023, its largest moves.
• Voyager Therapeutics' Research & Development stood at $14.6 million in 2022, then soared by 77.01% to $25.8 million in 2023, then surged by 38.15% to $35.6 million in 2024, then rose by 1.04% to $36.0 million in 2025, then slumped by 31.57% to $24.6 million in 2026.
• The last three Research & Development figures came in at $24.6 million (Q1 2026), $36.0 million (Q4 2025), and $35.9 million (Q3 2025), per Business Quant data.